From Medscape Oncology

Coverage from the

San Antonio Breast Cancer Symposium (SABCS) 2018

December 04 - 07, 2018; San Antonio, Texas

December 04 - 07, 2018 San Antonio, Texas

Meeting Highlights At A Glance

  • Top News From SABCS 2018: Slideshow Top News From SABCS 2018: Slideshow This year prominently featured major trials showing data in support of: a reduced dose and duration of tamoxifen for DCIS; partial breast irradiation; and a new standard of care when early-stage HER2+ disease is not cleared.

Conference News

Popular News from SABCS 2018

  • Top News From SABCS 2017: Slideshow Top News From SABCS 2017: Slideshow Hot topics include new data on the optimum duration of adjuvant therapy, the efficacy of trastuzumab in HER2–negative tumors, and the advantages of dose-dense chemotherapy.
  • Acupuncture Helps AI Pain; Insurers Should Cover, Say Trialists Acupuncture Helps AI Pain; Insurers Should Cover, Say Trialists In a randomized controlled trial that was praised as well designed, acupuncture improved pain and stiffness among breast cancer patients taking aromatase inhibitors (AIs).
  • 'Intriguing': 9 Weeks of Trastuzumab for Breast Cancer 'Intriguing': 9 Weeks of Trastuzumab for Breast Cancer Nine weeks of therapy fell short of being noninferior to 12 months for the primary outcome, but overall survival was comparable, and the shorter course is less toxic and less expensive.

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Medscape Oncology Insights

 

Previous Coverage